Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525935 · ClinicalTrials.gov registry record · Phase 2
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
A Phase 2 study, sponsored by Carmot Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 469
- Enrollment target
NCT06525935: Completed Phase 2 study, sponsored by Carmot Therapeutics.
NCT06525935 is a Phase 2 study that has completed, run by Carmot Therapeutics. The registered enrollment target is 469 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (253% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06525935, a Phase 2 study, has completed, sponsored by Carmot Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 469 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.
Interventions
- DRUG Placebo
- DRUG Enicepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 2 |
What the finished NCT06525935 record still lists
NCT06525935 is an interventional study that assigns participants to a tested intervention. The registered 469 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (253% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06525935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06525935 about?
NCT06525935 is a clinical study titled "A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity". This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.
What is the current status of trial NCT06525935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 469 participants. The study started on 2024-08-16. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT06525935?
The interventions under investigation include: Placebo (DRUG), Enicepatide (DRUG).
Who is sponsoring clinical trial NCT06525935?
This trial is sponsored by Carmot Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06525935's enrollment target sits among peer trials
469 80th of 2000 higher than 1,921 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI